Evaluation of the effectiveness of 2H-1,3-oxazine-2,6(3H)-dione (oxauracil) in the treatment of herpes simplex virus (HSV)-induced acute encephalitis in mice.
Treatment of suckling mice with the pyrimidine analogue 2H-1,3-oxazine-2,6(3H)-dione (oxauracil) proved successful in reducing mortality associated with HSV-2-induced encephalitis. Oxauracil did not decrease mortality associated with HSV-1 infection; however, there was an increased survival time and a decrease in the amount of infectious virus recovered from the brains of HSV-1-infected animals.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001921:Brain / Q000382:microbiology; D004341:Drug Evaluation; D004660:Encephalitis / Q000188:drug therapy* / Q000382:microbiology; D006561:Herpes Simplex / Q000188:drug therapy* / Q000382:microbiology; D051379:Mice; D010078:Oxazines; D018139:Simplexvirus / Q000302:isolation & purification; D014498:Uracil / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000998:Antiviral Agents; D010078:Oxazines; C015409:3-oxauracil; D014498:Uracil